Influence of radioimmunoscintigraphy on postprostatectomy radiotherapy treatment decision making

Journal of Nuclear Medicine

Volumn 45, Issue 4, 2004, Pages 571-578

  Jani, Ashesh B ^a,e   Blend, Michael J ^b   Hamilton, Russell ^c   Brendler, Charles ^a   Pelizzari, Charles ^a   Krauz, Lani ^a   Vijayakumar, Srinivasan ^d   Sapra, Bipin ^a   Awan, Azhar ^a   Weichselbaum, Ralph R ^a  

^a UNIVERSITY OF CHICAGO   (United States)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^c UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

Author keywords

Prostate cancer; Prostatectomy; Radioimmunoscintigraphy; Radiotherapy

Indexed keywords

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DECISION MAKING; HUMAN; IMMUNOSCINTIGRAPHY; KAPLAN MEIER METHOD; LYMPHADENOPATHY; MAJOR CLINICAL STUDY; MALE; PELVIS; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; BLOOD; CLINICAL PRACTICE; CLINICAL TRIAL; DECISION SUPPORT SYSTEM; METHODOLOGY; MIDDLE AGED; MULTICENTER STUDY; POSTOPERATIVE CARE; PROGNOSIS; PROSTATE TUMOR; RADIOIMMUNOASSAY; RISK ASSESSMENT; SCINTISCANNING; TUMOR RECURRENCE; VALIDATION STUDY;

PROSTATE SPECIFIC ANTIGEN;

AGED; AGED, 80 AND OVER; DECISION MAKING, COMPUTER-ASSISTED; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PHYSICIAN'S PRACTICE PATTERNS; POSTOPERATIVE CARE; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; RADIOIMMUNODETECTION; RISK ASSESSMENT;

EID: 2542494242     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Gronberg H. Prostate cancer epidemiology. Lancet. 2003;361:859-864.
2. Potosky AL, Feuer EJ, Levin DL. Impact of screening on incidence and mortality of prostate cancer in the United States. Epidemiol Rev. 2001;23:181-186.
3. Neal DE, Donovan JL. Prostate cancer: to screen or not to screen? Lancet Oncol. 2000;1:17-24.
4. Jani AB, Hellman S. Early prostate cancer: clinical decision-making. Lancet. 2003;361:1045-1053.
5. Sokoloff MH, Brendler CB. Indications and contraindications for nerve-sparing radical prostatectomy. Urol Clin North Am. 2001;28:535-543.
6. Hanlon AL, Hanks GE. Failure patterns and hazard rates for failure suggest the cure of prostate cancer by external beam radiation. Urology. 2000;55:725-729.
7. Anscher MS, Clough R, Dodge R. Radiotherapy for a rising prostate-specific antigen after radical prostatectomy: the first 10 years. Int J Radiat Oncol Biol Phys. 2000;48:369-375.
8. Schild SE, Buskirk SJ, Wong WW, et al. The use of radiotherapy for patients with isolated elevation of serum prostate specific antigen following radical prostatectomy. J Urol. 1996;156:1725-1729.
9. Petrovich Z, Lieskovsky G, Langholz B, Jozsef G, Streeter OE Jr, Skinner DG. Postoperative radiotherapy in 423 patients with pT3N0 prostate cancer. Int J Radiat Oncol Biol Phys. 2002;53:600-609.
10. Kalapurakal JA, Huang CF, Neriamparampil MM, et al. Biochemical disease-free survival following adjuvant and salvage irradiation after radical prostatectomy. Int J Radiat Oncol Biol Phys. 2002;54:1047-1054.
11. Manyak MJ, Hinkle GH, Olsen JO, et al. Immunoscintigraphy with indium-111-capromab pendetide: evaluation before definitive therapy in patients with prostate cancer. Urology. 1999;54:1058-1063.
12. Quintana JC, Blend MJ. The dual-isotope ProstaScint imaging procedure: clinical experience and staging results in 145 patients. Clin Nucl Med. 2000;25:33-40.
13. Hinkle GH, Burgers JK, Neal CE, et al. Multicenter radioimmunoscintigraphic evaluation of patients with prostate carcinoma using indium-111 capromab pendetide. Cancer. 1998;83:739-747.
14. Murphy GP, Elgamal AA, Troychak MJ, Kenny GM. Follow-up ProstaScint scans verify detection of occult soft-tissue recurrence after failure of primary prostate cancer therapy. Prostate. 2000;42:315-317.
15. Sodee DB, Malguria N, Faulhaber P, Resnick MI, Albert J, Bakale G. Multicenter ProstaScint imaging findings in 2154 patients with prostate cancer: the ProstaScint Imaging Centers. Urology. 2000;56:988-993.
16. Blend MJ, Sodee DB. ProstaScint: an update. In: Freeman LM, ed. Nuclear Medicine Annual 2001. Philadelphia, PA: Lippincott Williams and Wilkins; 2001:109-142.
17. Polascik TJ, Manyak MJ, Haseman MK, et al. Comparison of clinical staging algorithms and 111indium-capromab pendetide immunoscintigraphy in the prediction of lymph node involvement in high risk prostate carcinoma patients. Cancer. 1999;85:1586-1592.
18. Kahn D, Williams RD, Haseman MK, et al. Radioimmunoscintigraphy with In-111-labeled capromab pendetide predicts prostate cancer response to salvage radiotherapy after failed radical prostatectomy. J Clin Oncol. 1998;16:284-289.
19. Thomas CT, Bradshaw PT, Pollock BH, et al. Indium-111-capromab pendetide radioimmunoscintigraphy and prognosis for durable biochemical response to salvage radiation therapy in men after failed prostatectomy. J Clin Oncol. 2003;21:1715-1721.
20. Ellis RJ, Sodee DB, Spirnak JP, et al. Feasibility and acute toxicities of radioimmunoguided prostate brachytherapy. Int J Radiat Oncol Biol Phys. 2000;48:683-687.
21. Ellis RJ, Kim EY, Conant R, et al. Radioimmunoguided imaging of prostate cancer foci with histopathological correlation. Int J Radiat Oncol Biol Phys. 2001;49:1281-1286.
22. Cox JD, Gallagher MJ, Hammond EH, Kaplan RS, Schellhammer PF. Consensus statements on radiation therapy of prostate cancer: guidelines for prostate rebiopsy after radiation and for radiation therapy with rising prostate-specific antigen levels after radical prostatectomy. J Clin Oncol. 1999;17:1155.
23. Fleming TR, Lin DY. Survival analysis in clinical trials: past developments and future directions. Biometrics. 2000;56:971-983.
24. Bowker AH. A test for symmetry in contingency tables. J Am Stat Assoc. 1948;43:572-574.
25. Stuart A. A test for homogeneity of the marginal distributions in a two way classification. Biometrika. 1955;42;412-416.
26. Maxwell AE. Comparing the classification of subjects by two independent judges. Br J Psychiat. 1970;116:651-655.
27. Hamilton RJ, Blend MJ, Pelizzari CA, Milliken BD, Vijayakumar S. Using vascular structure for CT-SPECT registration in the pelvis. J Nucl Med. 1999;40:347-351.
28. Jani AB, Spelbring D, Hamilton R, et al. Impact of radioimmunoscintigraphy on definition of clinical target volume for radiotherapy after prostatectomy. J Nucl Med. 2004;45:238-246.